Risk factors
Rezolute (RZLT) risk factors
Item 1A of every Rezolute, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors32 risks8 new4 dropped2 reworded
FDA may reject a viable path for ersodetug in congenital HI or require a costly new randomized study after sunRIZE.
Filed Sep 24, 2026 - FY2025 10-K risk factors28 risks4 new7 dropped4 reworded
Rezolute is focusing on commercial readiness, adding growth and market capitalization risks as it scales past a $678.4M valuation. The company updated macroeconomic and tax risk factors to explicitly incorporate tariffs, trade policy, and federal tax changes.
Filed Sep 17, 2025 - FY2024 10-K risk factors31 risks
Rezolute faces primary risks around clinical trial execution, regulatory approvals, third-party manufacturing dependencies, and patent protection for its drug candidates.
Filed Sep 19, 2024